Literature DB >> 26845595

Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.

Mohamed Shoreibah1, Evan Raff2, Joseph Bloomer1, Donny Kakati1, Khalid Rasheed3, Yong-Fang Kuo4, Ashwani K Singal1.   

Abstract

BACKGROUND AND
OBJECTIVE: Steatohepatitis is a common cause of liver disease due to alcohol (ALD) or non-alcoholic fatty liver disease (NAFLD). We performed this study to compare natural history of ALD and NAFLD.
MATERIAL AND METHODS: Retrospective analysis of ALD or NAFLD patients managed at our center (2007-2011). ALD diagnosed by excluding other liver diseases (except HCV) and alcohol abuse of > 40 g/d in women and > 60 g/d in men for > 5 years. NAFLD diagnosed by excluding other liver diseases and a history of alcohol use of < 10 g/d. Cirrhosis was diagnosed using biopsy for uncertain clinical diagnosis.
RESULTS: Compared to patients with NAFLD (n = 365; mean age 50 yrs; 43% males; 53% diabetic), ALD patients (n = 206; mean age 51 yrs; 68% males; 24% diabetic) presented more often with cirrhosis or complications(46vs. 12%; P< 0.0001) with a higher MELD score (13 ± 7 vs. 8 ± 8; P<0.0001). On logistic regression, ALD diagnosis was associated with presence of cirrhosis by over 4-fold (4.1 [1.8-9.1]) even after excluding 23 patients with concomitant HCV. Over median follow up of about 3 and 4 yrs among ALD and NAFLD patients respectively, ALD patients more frequently developed cirrhosis or its complications including HCC with worse transplant free survival (90 vs. 95%; P = 0.038).
CONCLUSIONS: Compared to NAFLD, ALD patients present at an advanced stage of liver disease with a faster progression on follow-up. Prospective multicenter studies are needed to identify potential barriers to early referral of ALD patients as basis for development of strategies to improve outcome of patients with ALD.

Entities:  

Mesh:

Year:  2016        PMID: 26845595     DOI: 10.5604/16652681.1193707

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  9 in total

1.  Similarities and differences between non-alcoholic fatty liver disease (NAFLD) & alcohol-associated liver disease (ALD).

Authors:  Ashwani K Singal
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

2.  Second-harmonic generation (SHG) microscopy and hepatic venous pressure gradient-based validation of a novel histological staging system for alcoholic hepatitis.

Authors:  Archana Rastogi; Nayana Patil; Rakhi Maiwall; Chhagan Bihari; Ananda Soshee; Shiv K Sarin
Journal:  Virchows Arch       Date:  2021-04-02       Impact factor: 4.064

3.  Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide.

Authors:  Neil D Shah; Meritxell Ventura-Cots; Juan G Abraldes; Mohamed Alboraie; Ahmad Alfadhli; Josepmaria Argemi; Ester Badia-Aranda; Enrique Arús-Soler; A Sidney Barritt; Fernando Bessone; Marina Biryukova; Flair J Carrilho; Marlen Castellanos Fernández; Zaily Dorta Guiridi; Mohamed El Kassas; Teo Eng-Kiong; Alberto Queiroz Farias; Jacob George; Wenfang Gui; Prem H Thurairajah; John Chen Hsiang; Azra Husić-Selimovic; Vasily Isakov; Mercy Karoney; Won Kim; Johannes Kluwe; Rakesh Kochhar; Narendra Dhaka; Pedro Marques Costa; Mariana A Nabeshima Pharm; Suzane K Ono; Daniela Reis; Agustina Rodil; Caridad Ruenes Domech; Federico Sáez-Royuela; Christoph Scheurich; Way Siow; Nadja Sivac-Burina; Edna Solange Dos Santos Traquino; Fatma Some; Sanjin Spreckic; Shiyun Tan; Julio Vorobioff; Andrew Wandera; Pengbo Wu; Mohamed Yacoub; Ling Yang; Yuanjie Yu; Nerma Zahiragic; Chaoqun Zhang; Helena Cortez-Pinto; Ramon Bataller
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-29       Impact factor: 11.382

4.  Transgenic overexpression of CTRP3 prevents alcohol-induced hepatic triglyceride accumulation.

Authors:  Greta Trogen; Joshua Bacon; Ying Li; Gary L Wright; Ashley Degroat; Kendra L Hagood; Zachary Warren; Allan Forsman; Aruna Kilaru; W Andrew Clark; Jonathan M Peterson
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-05-15       Impact factor: 4.310

Review 5.  Liver fibrosis: Pathophysiology and clinical implications.

Authors:  Jennifer Berumen; Jacopo Baglieri; Tatiana Kisseleva; Kristin Mekeel
Journal:  WIREs Mech Dis       Date:  2020-07-26

Review 6.  Alcoholic Hepatitis: Lost in Translation.

Authors:  Benjamin L Woolbright; Hartmut Jaeschke
Journal:  J Clin Transl Hepatol       Date:  2017-12-17

7.  The sex specific effect of alcohol consumption on circulating levels of CTRP3.

Authors:  Ashley R DeGroat; Christina K Fleming; Samantha M Dunlay; Kendra L Hagood; Jonathan P Moorman; Jonathan M Peterson
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

8.  Racial and Health Disparities among Cirrhosis-related Hospitalizations in the USA.

Authors:  Ashwani K Singal; Yong-Fang Kuo; Juan P Arab; Ramon Bataller
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

9.  Contribution of a genetic risk score to ethnic differences in fatty liver disease.

Authors:  Maddie J Kubiliun; Jonathan C Cohen; Helen H Hobbs; Julia Kozlitina
Journal:  Liver Int       Date:  2022-06-06       Impact factor: 8.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.